Home>Topics>Companies>Novo Nordisk

Novo Nordisk

  1. All
  2. Commentary
  3. Stock Reports
  4. Video Reports
  5. Fund Reports
  6. ETF Reports
  7. Headlines
  1. Denmark's Novo Nordisk accepts fine for late disclosure of drug setback

    Headlines

    Mon, 18 Aug 2014

    COPENHAGEN, Aug 18 (Reuters) - Novo Nordisk A/S said on Monday it had accepted a near $90,000 fine from Danish regulators for failing to inform investors quickly enough that a drug it had hoped would become its next growth driver had been refused U.S. approval.

  2. New Morningstar Analyst Report for MannKind Corp

    Stock Reports

    Wed, 13 Aug 2014

    cancer in former smokers prompted diabetes experts such as Novo Nordisk and Eli Lilly to discontinue their inhaled insulin products ..... insulin class with a negative stigma. Diabetes giants such as Novo and Lilly have pulled their inhaled insulins from development

  3. Novo Nordisk : September 11 Could See A Big U.S. Market Catalyst

    Headlines

    Mon, 11 Aug 2014

    next two months are going to be very interesting for Novo Nordisk (NYSE: NVO ) - a large cap pharma company with a strong position in the insulin segment. Novo Nordisk is one of those companies that just keeps doing incredibly

  4. Novo Nordisk A/S's ( NVO ) CEO Lars Sørensen on Q2 2014 Results - Earnings Call Transcript

    Headlines

    Fri, 8 Aug 2014

    Novo Nordisk A/S (NYSE: NVO ) Q2 2014 Earnings Call ..... Executive Vice President Jesper Brandgaard - Chief Financial Officer ..... Chairman of the Board - Novo Nordisk Engineering A/S and Chairman of the Board - Novo Nordisk IT A/S Presentation

  5. Novo Nordisk lowers income guidance after Q2 results

    Headlines

    Thu, 7 Aug 2014

    Novo Nordisk ( NVO -2.2% ) Q2 results ((DKK M)): 21,629 (+6.3%); Gross Profit: 17,958 (+6.4%); Operating Income: 8

  6. Novo Nordisk A/S ( NVO ) Q2 2014 Results - Earnings Call Webcast

    Headlines

    Thu, 7 Aug 2014

    The following audio is from a conference call that will begin on August 07, 2014 at 07:00 AM ET. The audio will stream live while the call is active, and can be replayed upon its completion. Listen now Complete Story »

  7. Novo Nordisk Reports in Line Quarter; Slightly Raising FVE With Tresiba Outcomes Trial Progress

    Commentary

    Thu, 7 Aug 2014

    Novo Nordisk reported second-quarter results that were ..... s launch in the United States. We think Novo 's strong portfolio of diabetes therapies ..... innovation give the firm a stable, wide moat. Novo 's top line grew by 1% to DKK 21.6 billion

  8. Novo Nordisk beats by DKK0.06

    Headlines

    Thu, 7 Aug 2014

    Novo Nordisk (NYSE: NVO ): Q2 EPS of DKK2.66 beats by DKK0.06 . Revenue of DKK21.63B (+1.2% Y/Y) Press Release Post your comment!

  9. UPDATE 2- Novo Nordisk aims for 2016 Tresiba launch in U.S.

    Headlines

    Thu, 7 Aug 2014

    * Shares up 1.5 pct (Adds comments from CEO, analysts, share price)

  10. Novo Nordisk says FDA approval for Tresiba could come end-2015

    Headlines

    Thu, 7 Aug 2014

    COPENHAGEN, Aug 7 (Reuters) - Novo Nordisk could receive an approval from the U.S. Food and Drug Administration for Tresiba by the end of next year, paving the way for its launch in the United States at the start of 2016, the company's chief executive said on Thursday.

« Prev12345Next »
Content Partners